Music composer Shravan Rathod hospitalized after testing positive for Covid-19; Reports say “his condition is critical”
Famous music composer Shravan Rathod is currently undergoing treatment at a hospital in Mumbai and reports say that his condition is critical...
Published: Monday,Apr 19, 2021 10:16 AM GMT-06:00
Celebrated music composer Shravan Rathod, of Nadeem-Sharvan fame, has been admitted to the Raheja Hospital at Mahim, Mumbai - after he was tested positive for Covid-19. The composer is currently undergoing treatment and as per the recent reports, his condition is critical as he has co-morbidities.
An ETimes report quoted Dr Kriti Bhushan - who is overseeing the musician’s health at the hospital and informed that Shravan is undergoing the necessary treatment.
He said, "Shravan Rathod is on ventilator support and his condition is critical. There is a bit of heart enlargement and his pumping has been affected. We are taking the necessary steps for the same. We have made a medical team of physicians, cardiologists, a diabetologist and an intensivist, all of who are overseeing his care."
Reports suggest that Sharvan’s condition has not deteriorated post-admission but is still very critical.
Shravan's close friend, lyricist Sameer was quoted by ETimes, who also confirmed that the singer is in a critical condition.
Sameer added, “Shravan is diabetic and with this infection, his lungs have been totally infected. He has also developed heart issues, please pray to God almighty for his speedy recovery.''
Meanwhile, BMC officials will soo visit his house to test his wife for COVID-19.
For the unversed, Shravan is known for his composition for hit films like Saajan, Raja Hindustani and Pardes, in collaboration with his flamboyant partner Nadeem.
The legendary musician duo have belted out hits for films like ‘Dil Hai Ke Maanta Nahin’, ‘Saajan’, ‘Sadak’, ‘Deewana’ and ‘Pardes’ to name a few.
his composition for hit films like Saajan, Raja Hindustani and Pardes.
ALSO READ: Shivam Khajuria to join Anupamaa as Aadhya's love interest post-leap: Reports
Comments (0)